Drugs Made In America Acquisition II Corp（DMII）美股招股说明书 S-1 （2025-09-05修订版）（英文版）（205页）.pdf

《Drugs Made In America Acquisition II Corp（DMII）美股招股说明书 S-1 （2025-09-05修订版）（英文版）（205页）.pdf》由会员分享，可在线阅读，更多相关《Drugs Made In America Acquisition II Corp（DMII）美股招股说明书 S-1 （2025-09-05修订版）（英文版）（205页）.pdf（205页珍藏版）》请在三个皮匠报告上搜索。

1、As filed with the U.S.Securities and Exchange Commission under theSecurities Actof1933,asamended,on September 5,2025.Registration No.333-288791UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549_Amendment No.1 toFORM S-1REGISTRATION STATEMENTUNDERTHE SECURITIES ACT OF 1933_Drugs Made

2、 In America AcquisitionII Corp.(Exact name of registrant as specified in its charter)_Cayman Islands677098-1815624(Stateorotherjurisdictionofincorporationororganization)(PrimaryStandardIndustrialClassificationCodeNumber)(I.R.S.EmployerIdentificationNumber)Lynn StockwellChief Executive Officer and Ex

3、ecutive ChairDrugs Made In America AcquisitionII Corp.1 East Broward Boulevard,Suite 700Fort Lauderdale,FL33301(954)870-3099(Address,including zip code,and telephone number,including area code,ofregistrants principal executive offices)_Copies to:Mitchell S.Nussbaum,Esq.G.Alex Weniger-Araujo,Esq.Loeb

4、&Loeb LLP345 Park AvenueNewYork,NY10154Tel:(212)407-4000Douglas S.Ellenoff,Esq.Stuart Neuhauser,Esq.Anthony Ain,Esq.Ellenoff Grossman&Schole LLP1345 Avenue of the AmericasNewYork,NY10105(212)370-1300_Approximate date of commencement of proposed sale to the public:As soon as practicable after the eff

5、ectivedate of this registration statement.If any of the securities being registered on this Form are to be offered on a delayed or continuous basispursuant to Rule415 under the Securities Actof1933 check the following box:If this Form is filed to register additional securities for an offering pursua

6、nt to Rule462(b)under theSecurities Act,please check the following box and list the Securities Act registration statement number of theearlier effective registration statement for the same offering.If this Form is a post-effective amendment filed pursuant to Rule462(c)under the Securities Act,check